Kumondai M, Rico E, Hishinuma E, Nakanishi Y, Yamazaki S, Ueda A
J Pers Med. 2021; 11(8).
PMID: 34442334
PMC: 8401128.
DOI: 10.3390/jpm11080690.
Lee J, Kim S, Lee K, Oh S
Adv Exp Med Biol. 2021; 1310:533-550.
PMID: 33834449
DOI: 10.1007/978-981-33-6064-8_20.
Henriques B, Yang E, Lapetina D, Carr M, Yavorskyy V, Hague J
Front Genet. 2020; 11:491895.
PMID: 33363564
PMC: 7753050.
DOI: 10.3389/fgene.2020.491895.
James A, Schiller H, Marvalin C, Jin Y, Borell H, Roffel A
Pharmacol Res Perspect. 2020; 8(3):e00599.
PMID: 32524755
PMC: 7287031.
DOI: 10.1002/prp2.599.
Liu Y, Hu K, Wang Y
Polymers (Basel). 2019; 9(6).
PMID: 30970894
PMC: 6431835.
DOI: 10.3390/polym9060215.
In Vitro and In Vivo Drug Interaction Study of Two Lead Combinations, Oxantel Pamoate plus Albendazole and Albendazole plus Mebendazole, for the Treatment of Soil-Transmitted Helminthiasis.
Cowan N, Vargas M, Keiser J
Antimicrob Agents Chemother. 2016; 60(10):6127-33.
PMID: 27480864
PMC: 5038309.
DOI: 10.1128/AAC.01217-16.
Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.
Godoy P, Hewitt N, Albrecht U, Andersen M, Ansari N, Bhattacharya S
Arch Toxicol. 2013; 87(8):1315-530.
PMID: 23974980
PMC: 3753504.
DOI: 10.1007/s00204-013-1078-5.
Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
Jiang F, Desta Z, Shon J, Yeo C, Kim H, Liu K
Br J Clin Pharmacol. 2012; 75(1):244-53.
PMID: 22554354
PMC: 3555064.
DOI: 10.1111/j.1365-2125.2012.04314.x.
Effect of Ginkgo biloba special extract EGb 761® on human cytochrome P450 activity: a cocktail interaction study in healthy volunteers.
Zadoyan G, Rokitta D, Klement S, Dienel A, Hoerr R, Gramatte T
Eur J Clin Pharmacol. 2011; 68(5):553-60.
PMID: 22189672
PMC: 3332346.
DOI: 10.1007/s00228-011-1174-5.
Assessment of compound hepatotoxicity using human plateable cryopreserved hepatocytes in a 1536-well-plate format.
Moeller T, Shukla S, Xia M
Assay Drug Dev Technol. 2011; 10(1):78-87.
PMID: 22053711
PMC: 3277728.
DOI: 10.1089/adt.2010.0365.
Assessment of algorithms for predicting drug-drug interactions via inhibition mechanisms: comparison of dynamic and static models.
Guest E, Rowland-Yeo K, Rostami-Hodjegan A, Tucker G, Houston J, Galetin A
Br J Clin Pharmacol. 2010; 71(1):72-87.
PMID: 21143503
PMC: 3018028.
DOI: 10.1111/j.1365-2125.2010.03799.x.
A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.
Venkatakrishnan K, Pickard M, von Moltke L
Clin Pharmacokinet. 2010; 49(11):703-27.
PMID: 20923246
DOI: 10.2165/11536740-000000000-00000.
Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase.
Greenblatt D, Peters D, Oleson L, Harmatz J, MacNab M, Berkowitz N
Br J Clin Pharmacol. 2009; 68(6):920-7.
PMID: 20002087
PMC: 2810804.
DOI: 10.1111/j.1365-2125.2009.03545.x.
Integration of preclinical and clinical data with pharmacokinetic modeling and simulation to evaluate fexofenadine as a probe for hepatobiliary transport function.
Swift B, Tian X, Brouwer K
Pharm Res. 2009; 26(8):1942-51.
PMID: 19495943
PMC: 3083979.
DOI: 10.1007/s11095-009-9909-z.
Multiple inhibition mechanisms and prediction of drug-drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil-drug interactions.
Hinton L, Galetin A, Houston J
Pharm Res. 2007; 25(5):1063-74.
PMID: 17901929
DOI: 10.1007/s11095-007-9446-6.
Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown H, Galetin A, Hallifax D, Houston J
Clin Pharmacokinet. 2006; 45(10):1035-50.
PMID: 16984215
DOI: 10.2165/00003088-200645100-00006.
Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes.
Zhang J, Liu Y, Li W, Hao D, Yang L
Eur J Clin Pharmacol. 2006; 62(7):497-502.
PMID: 16645869
DOI: 10.1007/s00228-006-0128-9.
Predictions of the in vivo clearance of drugs from rate of loss using human liver microsomes for phase I and phase II biotransformations.
Mohutsky M, Chien J, Ring B, Wrighton S
Pharm Res. 2006; 23(4):654-62.
PMID: 16550474
DOI: 10.1007/s11095-006-9663-4.
Differential in vitro inhibition of M3G and M6G formation from morphine by (R)- and (S)-methadone and structurally related opioids.
Morrish G, Foster D, Somogyi A
Br J Clin Pharmacol. 2006; 61(3):326-35.
PMID: 16487227
PMC: 1885024.
DOI: 10.1111/j.1365-2125.2005.02573.x.
Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans.
Bapiro T, Sayi J, Hasler J, Jande M, Rimoy G, Masselle A
Eur J Clin Pharmacol. 2005; 61(10):755-61.
PMID: 16261361
DOI: 10.1007/s00228-005-0037-3.
